Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus LERIBANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus LERIBANE.
IMPOYZ vs LERIBANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Leribane is a synthetic cannabinoid receptor agonist with high affinity for CB1 and CB2 receptors. It inhibits adenylate cyclase activity via Gi/o protein coupling, leading to decreased cAMP accumulation, modulation of ion channels, and inhibition of neurotransmitter release.
100 mg orally twice daily
5-10 mg orally twice daily; maximum 30 mg/day.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
24 hours (range 20-30 h); accumulates to steady state in ~5 days, requires dose adjustment in renal impairment
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Unknown
Unknown